Shareholders in AnaptysBio (NASDAQ:ANAB) Have Lost 60%, as Stock Drops 13% This Past Week

Simply Wall StDec 23 20:20

Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Maintains Target Price $20

Futu NewsDec 21 02:31 · Ratings

J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $36

Futu NewsDec 21 02:31 · Ratings

JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $36

BenzingaDec 20 01:05 · Ratings

Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Announces Target Price $20

Futu NewsDec 19 18:33 · Ratings

Stifel Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $41

Futu NewsDec 17 10:32 · Ratings